Holder evidence
6
SEC ownership of Oncotelic Therapeutics, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0000908259.
Lead holder
Vuong Trieu
13D/G signal
—
Latest evidence
22 Jan 2026
- CIK
- 0000908259
- Symbol
- OTLC on OTC
- Location
- Aguora Hills, CA
- SEC evidence mix
- 3/4/5
- Lead holder
- Vuong Trieu
- Latest evidence date
- 22 Jan 2026
Issuer identity
Ownership snapshot
Ownership snapshot
Top shareholders of Oncotelic Therapeutics, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Lead holder
Vuong Trieu
13D/G signal
—
Evidence rows
6
Latest as of
22 Jan 2026
3/4/5
Highest disclosed value: $7,022,471
Rank 1 holder
Vuong Trieu
3/4/5
- Ownership
- —
- Position
- $7.02M
Rank 2 holder
Amit B. Shah
3/4/5
- Ownership
- —
- Position
- $9.3K
Rank 3 holder
Saran Saund
3/4/5
- Ownership
- —
- Position
- —
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Vuong Trieu |
3/4/5
CHAIRMAN AND CEO, Director, 10%+ Owner
|
—
mixed-class rows
|
$7,022,471
117,049,701 shares
mixed-class rows
|
— | 22 Jan 2026 |
| Amit B. Shah |
3/4/5
CHIEF FINANCIAL OFFICER
|
—
mixed-class rows
|
$9,330
1,057,093 shares
mixed-class rows
|
— | 08 Jul 2021 |
| Saran Saund |
3/4/5
Chief Business Officer
|
—
class O/S missing
|
—
675,000 shares
|
— | 03 Sep 2021 |
| Anthony E. Maida III |
3/4/5
Chief Clin. Ops. Officer, Director
|
—
class O/S missing
|
—
600,000 shares
|
— | 03 Sep 2021 |
| Steven W. King |
3/4/5
Director
|
—
class O/S missing
|
—
500,000 shares
|
— | 03 Sep 2021 |
| David Diamond |
3/4/5
Director
|
—
class O/S missing
|
—
451,467 shares
|
— | 08 Jul 2021 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 31 May 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-6 of 6 reporting-owner rows connected to Oncotelic Therapeutics, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
6
Lead holder
Vuong Trieu
Net 12M change
$0
Latest report
22 Jan 2026
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Vuong Trieu | CHAIRMAN AND CEO, Director, 10%+ Owner | $7,022,471 | Mixed | 22 Jan 2026 | ||
| Amit B. Shah | Chief Financial Officer | $9,330 | Mixed | 08 Jul 2021 | ||
| Anthony E. Maida III | Chief Clin. Ops. Officer, Director | Mixed | 03 Sep 2021 | |||
| David Diamond | Director | Mixed | 08 Jul 2021 | |||
| Saran Saund | Chief Business Officer | Mixed | 03 Sep 2021 | |||
| Steven W. King | Director | Mixed | 03 Sep 2021 |
Recent insider transactions for Oncotelic Therapeutics, Inc.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Reported value | Reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Vuong Trieu | OTLC | Series A Convertible Preferred Stock | Award | 108.9% | 4,426 | 8,491 | 22 Jan 2026 | Direct | ||
| Vuong Trieu | OTLC | Series A Convertible Preferred Stock | Award | 4,065 | 4,065 | 17 Nov 2025 | Direct | |||
| Vuong Trieu | OTLC | Common Stock | Purchase | 0.11% | 104,000 | 93,293,560 | 10 Jul 2025 | Direct | ||
| Vuong Trieu | OTLC | Common Stock | Purchase | 1 | 93,293,561 | 09 Jul 2025 | Direct | |||
| Vuong Trieu | OTLC | Common Stock | Purchase | 0.1% | 94,736 | 93,388,297 | 08 Jul 2025 | Direct |
* indicates a reported price that failed the local validity check.